Professional Documents
Culture Documents
tmp20CA TMP
tmp20CA TMP
tmp20CA TMP
PHLMS&Acceptance&Scores(
BAFT%Scores!
40# 80"
60"
30#
40"
20# 20"
10# 0"
#
1#
#
3#
7#
"
1"
3"
7"
"
"
"
ke
10
U.
U.
ke
10
U.
U.
#F.
#F .
"F.
"F .
ta
ta
In
In
o.
ar
o.
ar
m
m
ye
ye
1#
1"
3#
3"
a)&&&&&&&&&&&&&&&&&&&&&&&&&Session&Number&& b)%%%%%%%%%%%%%%%%%%%%%%%%%Session%Number%%
30" 170#
AAQ#2%Total%Scores!
KMPAI&Scores!
25"
20" 120#
15"
10" 70#
5"
0" 20#
1"
"
3"
7"
"
"
1#
3#
7#
#
10
U.
U.
ke
10
U.
U.
"F.
"F .
#F.
#F .
ta
In
o.
ar
o.
ar
m
m
ye
ye
1"
1#
3"
3#
c)%%%%%%%%%%%%%%%%%%%%%%%%%Session%Number%% d)&&&&&&&&&&&&&&&&&&&&&&&&&Session&Number&&
Figure 2. a) PHLMS Acceptance subscale scores, and b) BAFT scores from intake (baseline) to
1-month follow-up and 3-year follow-up (June 2017) with non-clinical means and bars spanning
two standard deviations, bidirectionally. c) AAQ-2 scores from session 1 to 1-month follow-up
and 3-year follow-up (June 2017) with non-clinical mean and bars spanning two standard
deviations, bidirectionally. d) KMPAI scores from intake to 1-month follow-up and 3-year
follow-up (June 2017) with cutoff score for determining clinically significant levels of MPA.